GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange about change in Management
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Midcap 150 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
GSK Pharmaceuticals reported its FY25 audited results with standalone revenue from operations rising 9.3% YoY to Rs. 3,723 crore and net profit jumping 57% to Rs. 919 crore (vs Rs. 585 crore in FY24, which was hit by a one-time VRS charge). Q4 FY25 standalone profit grew about 35% YoY to Rs. 260 crore. The Board has recommended a final dividend of Rs. 42 per share (up from Rs. 32 last year, a 31% increase) on the face value of Rs. 10, subject to shareholder approval. The Board re-appointed Dr. Sunita Maheshwari as an Independent Director for a second term of three years and appointed Parikh & Associates as the new Secretarial Auditor for a first term of five years (FY26-FY30). The 100th AGM is fixed for 27th June 2025, with 30th May 2025 as the record date for the dividend.
Strong profit growth and a meaningful hike in dividend should be viewed positively by shareholders. Despite the headline suggesting a 'change in management,' there is no CEO/CFO/MD change — Bhushan Akshikar continues as Managing Director. The re-appointment of an existing Independent Director and the routine appointment of a Secretarial Auditor are standard corporate housekeeping items and unlikely to move the stock.